Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M P Goren

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
The Pediatric Infectious Disease Journal|October 1, 1988
Monitoring serum aminoglycoside concentrations in children with amphotericin B nephrotoxicityM P Goren, M J Viar, J L Shenep, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjectsM P Goren, J M Houle, D A Bush, et al.
Cancer Research|December 15, 1989
Mesna excretion and ifosfamide nephrotoxicity in childrenM P Goren, C B Pratt, W H Meyer, et al.
Cancer Research|July 1, 1988
Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patientsA A Forastiere, J F Belliveau, M P Goren, et al.
Cancer Treatment Reports|January 1, 1987
Phase I study of iproplatin in pediatric patients: a Pediatric Oncology Group StudyC B Pratt, B A Kamen, N Winick, et al.
Cancer Chemotherapy and Pharmacology|January 27, 1998
Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumorL Carlson, M P Goren, D A Bush, et al.
Cancer Research|March 1, 1987
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapyM P Goren, R K Wright, C B Pratt, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicityM P Goren, A A Forastiere, R K Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamideM P Goren, L B Anthony, K R Hande, et al.
Seminars in Oncology|February 1, 1989
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988C B Pratt, E C Douglass, E Etcubanas, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
The Pediatric Infectious Disease Journal|October 1, 1988
Monitoring serum aminoglycoside concentrations in children with amphotericin B nephrotoxicityM P Goren, M J Viar, J L Shenep, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjectsM P Goren, J M Houle, D A Bush, et al.
Cancer Research|December 15, 1989
Mesna excretion and ifosfamide nephrotoxicity in childrenM P Goren, C B Pratt, W H Meyer, et al.
Cancer Research|July 1, 1988
Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patientsA A Forastiere, J F Belliveau, M P Goren, et al.
Cancer Treatment Reports|January 1, 1987
Phase I study of iproplatin in pediatric patients: a Pediatric Oncology Group StudyC B Pratt, B A Kamen, N Winick, et al.
Cancer Chemotherapy and Pharmacology|January 27, 1998
Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumorL Carlson, M P Goren, D A Bush, et al.
Cancer Research|March 1, 1987
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapyM P Goren, R K Wright, C B Pratt, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicityM P Goren, A A Forastiere, R K Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamideM P Goren, L B Anthony, K R Hande, et al.
Seminars in Oncology|February 1, 1989
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988C B Pratt, E C Douglass, E Etcubanas, et al.
Pageof 5